Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31046903 | 1.00 | ALB (0.49) | ALBKMT2AACLYKDM4EALDH1A1 | |
| SCHEMBL221875 | 0.84 | TSHR (0.50) | KMT2AKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL10625562 | 0.82 | KEAP1 (0.46) | KMT2AALDH1A1ALOX15PLA2G7KEAP1 | |
| SCHEMBL27396813 | 0.81 | KMT2A (0.57) | KMT2AACLYKDM4EALDH1A1HSD17B10 | |
| SCHEMBL7554525 | 0.80 | MAP2K1 (0.48) | KMT2AACLYKDM4EALDH1A1HSD17B10 | |
| SCHEMBL7552241 | 0.80 | TSHR (0.50) | KMT2AACLYKDM4EALDH1A1ALOX15 | |
| SCHEMBL20303914 | 0.79 | ALB (0.55) | ALBKMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL29785235 | 0.79 | ALB (0.55) | ALBKMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL7556648 | 0.78 | ACLY (0.42) | ACLYALDH1A1HSD17B10CCR2 | |
| SCHEMBL20399271 | 0.77 | KMT2A (0.55) | KMT2AKDM4EALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-112204008-B | Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives | 奥索生物公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3796975-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2021-03-31 | — | — | EP | disclosed |
| CN-112204008-A | Sulphonylaminobenzylamide and sulphonylaminobenzamide derivatives | 吉利德科学公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-2838900-B1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | ALB 1411/4885KMT2A 1234/4885ACLY 2228/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | ALB 1411/4885KMT2A 1234/4885ACLY 2228/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | ALB 2375/4885KMT2A 3648/4885ACLY 3992/4885 |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | ALB 2375/4885KMT2A 3648/4885ACLY 3992/4885 |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | ALB 747/4885KMT2A 3849/4885ACLY 1556/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | ALB 2260/4885KMT2A 2071/4885ACLY 1624/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | ALB 1411/4885KMT2A 1234/4885ACLY 2228/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | ALB 1411/4885KMT2A 1234/4885ACLY 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.